MARKET

COLL

COLL

Collegium Pharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

20.44
+0.05
+0.25%
After Hours: 20.44 0 0.00% 16:00 09/24 EDT
OPEN
20.34
PREV CLOSE
20.39
HIGH
20.72
LOW
20.20
VOLUME
210.57K
TURNOVER
--
52 WEEK HIGH
26.91
52 WEEK LOW
17.24
MARKET CAP
726.94M
P/E (TTM)
7.52
1D
5D
1M
3M
1Y
5Y
Enlivex (ENLV) Begins Phase IIb COVID-19 Study on Cell Therapy
Zacks.com · 3d ago
COLL vs. ZTS: Which Stock Should Value Investors Buy Now?
Zacks.com · 6d ago
Top Pharmaceutical Stocks for Q4 2021
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2021.
Investopedia · 09/14 16:51
Collegium Announces Four Posters Presented at PAINWeek 2021 National Conference
STOUGHTON, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that four poster presentations highlighting...
GlobeNewswire · 09/13 12:00
Collegium to Participate in Upcoming Investor Conferences
STOUGHTON, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the fol...
GlobeNewswire · 09/01 20:01
5 Value Stocks To Watch In The Healthcare Sector
What are Value Stocks?
Benzinga · 08/30 14:22
Hot Stocks: Chinese EV stocks weighed down by regulatory worries; EPIX, MCW decline; COLL, HHR advance
Worries about regulation have swirled lately around both Big Tech and Chinese stocks. These conspired to drag down a specific segment of the Chinese tech market on Monday, as China-based
Seekingalpha · 08/16 21:16
Mid-Afternoon Market Update: Dow Turns Positive; Sesen Bio Shares Plummet
Toward the end of trading Monday, the Dow traded up 0.03% to 35,526.99 while the NASDAQ fell 0.34% to 14,771.91. The S&P also rose, gaining 0.02% to 4,468.88.
Benzinga · 08/16 18:32
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of COLL. Analyze the recent business situations of Collegium Pharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average COLL stock price target is 26.71 with a high estimate of 36.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 241
Institutional Holdings: 39.94M
% Owned: 112.31%
Shares Outstanding: 35.56M
TypeInstitutionsShares
Increased
61
1.83M
New
15
345.21K
Decreased
43
785.98K
Sold Out
19
1.40M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.45%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Director
Michael Heffernan
President/Chief Executive Officer/Director
Joseph Ciaffoni
Chief Financial Officer/Executive Vice President
Colleen Tupper
Executive Vice President/Chief Technology Officer
Alison Fleming
Executive Vice President/General Counsel/Secretary
Shirley Kuhlmann
Executive Vice President
Scott Dreyer
Executive Vice President
Richard Malamut
Lead Director/Independent Director
Gino Santini
Independent Director
Rita Balice-Gordon
Independent Director
Garen Bohlin
Independent Director
John Fallon
Independent Director
John Freund
Independent Director
Gwen Melincoff
Independent Director
Theodore Schroeder
No Data
  • All
  • Financials
  • Insiders
More
About COLL
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

Webull offers kinds of Collegium Pharmaceutical Inc stock information, including NASDAQ:COLL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, COLL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading COLL stock methods without spending real money on the virtual paper trading platform.